Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | TEK | Q02763 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16775983 | 0.90 | HDAC2 (0.39) | CACNA1GCACNA1HCACNA1IRPS6KA2ATR | |
| SCHEMBL16775991 | 0.88 | THRB (0.39) | ATRTHRBGRM5 | |
| SCHEMBL16775989 | 0.88 | RPS6KA3 (0.41) | RPS6KA3RPS6KA2ATRPRKDC | |
| SCHEMBL16775979 | 0.87 | CREBBP (0.44) | ATRBRAFTHRB | |
| SCHEMBL16775942 | 0.86 | HDAC2 (0.37) | — | |
| SCHEMBL16775993 | 0.85 | ABL1 (0.43) | RPS6KA3RPS6KA2ABL1BCRTEK | |
| SCHEMBL16775980 | 0.85 | GRM5 (0.39) | ARGRM5 | |
| SCHEMBL16776187 | 0.84 | RPS6KA3 (0.41) | CACNA1GCACNA1HCACNA1IRPS6KA3RPS6KA2 | |
| SCHEMBL16775933 | 0.84 | USP30 (0.39) | ARGRM5 | |
| SCHEMBL16775992 | 0.83 | GRM5 (0.40) | BRAFGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CACNA1G 4560/4885CACNA1H 4445/4885CACNA1I 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.